00:00Cancer remains a global crisis, with nearly 20 million new cases diagnosed in 2022 alone, according to the World Health Organization.
00:12The hardest hit nations include China with over 4.8 million cases, the United States at 2.4 million, India with about 1.4 million and Japan at 1.3 million, highlighting the urgent need for breakthroughs.
00:29Russia is stepping up with two cutting-edge vaccines, poised to transform treatment by late 2025, developed by leading institutes like the Gamaleya Center. These therapies offer new hope to millions.
00:44First up, a personalized mRNA vaccine, built on technology from Russia's Sputnik V COVID-19 vaccine. Here is how it works.
00:54A tumor sample is sequenced to identify unique mutations. Artificial intelligence then designs a custom vaccine in under and half, instructing the body to produce proteins that mimic cancer cells, training the immune system to attack.
01:10Pre-clinical trials on animals showed it suppresses tumor growth and stops metastasis.
01:17Women trial for melanoma kicked off in August 2025, with plans to target other cancers soon.
01:25The second breakthrough is Enterobics, an oncolytic vaccine using a mix of harmless viruses to directly attack cancer cells, by boosting immunity.
01:37Tested for chloroactyl cancer, brain tumors and melanoma, it reduced tumors by 60 to 80% in pre-clinical studies, with minimal side effects.
01:48clinical trials began in June 2025, and it's now awaiting final health ministry approval for free distribution to Russian patients.
01:59With over 4 million cancer cases in Russia, the government is funding these vaccines, making them free for patients, despite the mRNA version costing $3,800 per dose.
02:13This focus on accessibility could redefine cancer care, but experts caution, no peer-reviewed human trial data is available yet, and these therapies work alongside surgery or care book, not as replacement.
02:30Russia's efforts align with global mRNA vaccine trials in the United Kingdom and United States, but transparency is critical.
02:40For the latest update on this promising story, stay tuned to all our social platforms at Cardio Nigeria.
Be the first to comment